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Background
Cancer is a dreadful disease and remains a major cause
of mortality world-wide. Plant derived compounds such
as vincristine, vinblastine, etoposide, camptothecin etc.
are widely used in cancer therapeutics. Nigella sativa
(Figure 1) is claimed to have antihypertensive, analgesic,
diuretic, anti-bacterial and liver protective effects [1];
however, there are only very few scientific evidence. In
the present study, we attempt to explore the anticancer
cancer claims of Nigella sativa, on human hepatocellular
adenocarcinoma (HepG2) cell line in vitro.
Materials and methods
The whole extract of Nigella sativa (generously donated
by the ENT research group, KAUH) was filter sterilized
using 0.2µm syringe filters. The HepG2 cells were seeded
at 3 x 104 cells/well of a 24-well tissue culture plate and
cultured overnight in DMEM low glucose medium supple-
mented with 10% fetal bovine serum, 200mM GlutaMax,
1% penicillin/streptomycin under standard culture condi-
tions of 37°C in a 5% CO2 air atmosphere. Following addi-
tion of fresh medium, Nigella sativa extract was added at
various concentrations namely 0.1%, 0.3%, 0.5, 0.7%, and
1%; and the cells cultured for 24 h and 48 h. Nigella sativa
extract was not added to the control wells. Changes in cell
morphology was imaged using inverted phase contrast
optics and the cell viability was assessed by MTT assay.
Results
Control HepG2 cells maintained their typical morphol-
ogy and formed a confluent monolayer. In contrast, the
cells treated with Nigella sativa extract showed varying
changes in morphology (cell shrinkage, membrane
damage) resulting in cell death and gross decreases in
cell numbers starting from 0.3% concentration at both
24 h and 48 h (Figure 1B). MTT assay demonstrated
statistically significant decreases in cell proliferation
with increasing concentrations of the drug at 24 h and
48 h. The mean decreases in cell proliferation were 18%,
42%, 54%, 56%, and 62% at 24hr; and 23%, 27%, 36%,
38% and 53% at 48hr for the concentrations 0.1%, 0.3%,
0.5%, 0.7% and 1% respectively (Figure 1C, 1D).
Conclusions
In the present study, the extract of Nigella sativa
demonstrated inhibition of HepG2 cell line in vitro. Our
results are in accordance with an earlier study [2] where
a different form of Nigella sativa extract was found to
inhibit the growth and proliferation of the HepG2. We
therefore conclude that Nigella sativa extract has antic-
ancer properties which needs further exploration and as
such we are currently involved in identifying the active
ingredient of the extract as well as the underlying mole-
cular mechanism leading to cell death.
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Figure 1 (A). Photograph of Nigella sativa plant, flower and seeds (inset). (B). Phase contrast microscopic images showing the HepG2 cell
morphology of control and treated groups (0.1%, 0.3% and 1% Niegella sativa extract at 24 h).The short black arrow indicates dead cells and the
arrow head indicates cell shrinkage. (C, D). Cell proliferation (MTT assay) results of Hep G2 cell line following treatment with Nigella sativa extract
at varying concentrations (0.1%, 0.3%,0.5%,0.7% and 1%) for 24 h (C) incubation and 48 h (D). All values are expressed as mean ± SEM from
three different replicates.
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